Product Code: ETC069959 | Publication Date: Aug 2023 | Updated Date: Jan 2024 | Product Type: Report | |
Publisher: 6Wresearch | No. of Pages: 70 | No. of Figures: 35 | No. of Tables: 5 | |
The United Arab Emirates (UAE) biosimilars market has been witnessing steady growth, driven by the increasing demand for cost-effective and high-quality biologic medicines. Biosimilars are biological products that are highly similar to approved reference biologics, offering a more affordable alternative for patients and healthcare systems. In the UAE, as the government focuses on expanding access to healthcare and reducing healthcare expenditure, the adoption of biosimilars has gained traction. The market`s growth is influenced by the UAE robust regulatory framework for biosimilars, the prevalence of chronic diseases, and the impact of the Covid-19 pandemic on healthcare systems.
The growth of the UAE biosimilars market is propelled by several key drivers. Firstly, the rising burden of chronic diseases, such as cancer, autoimmune disorders, and diabetes, has increased the demand for biologic therapies. Biosimilars offer cost-effective treatment options, allowing a broader population to access these life-saving medications. Secondly, the UAE government`s initiatives to promote healthcare sustainability and cost containment have led to the inclusion of biosimilars in national formularies and treatment guidelines, encouraging their adoption in healthcare facilities.
Despite the positive market outlook, the UAE biosimilars market faces certain challenges. One significant challenge is the complexity of biosimilar development and regulatory approval. Manufacturers must demonstrate a high degree of similarity and comparability to reference biologics through extensive clinical studies, which can be resource-intensive and time-consuming. Additionally, ensuring patient and physician confidence in biosimilars` safety and efficacy is crucial to drive their acceptance and adoption.
The Covid-19 pandemic, which emerged in 2020, had a notable impact on the UAE biosimilars market. The pandemic put immense pressure on healthcare systems, leading to a heightened focus on cost-saving strategies and the need for affordable treatment options. Biosimilars, as cost-effective alternatives to reference biologics, became a key consideration for healthcare providers and policymakers to manage the increased demand for healthcare services during the pandemic.
The UAE biosimilars market is experiencing robust growth, driven by an increasing focus on cost-effective healthcare solutions and the rising demand for biologic drugs. As governments and healthcare providers strive to improve accessibility to advanced treatments, biosimilars offer a compelling option for patients and healthcare systems. Key players leading this thriving market include pharmaceutical giants such as Sandoz International GmbH (a subsidiary of Novartis), Pfizer Inc., and Amgen Inc. These industry leaders are actively investing in research and development to develop high-quality biosimilars that meet stringent regulatory standards, providing safe and affordable alternatives to expensive biologics. Additionally, local players like Julphar Gulf Pharmaceutical Industries and Neopharma are making significant contributions to the market`s growth, reinforcing the country`s position as a hub for biosimilar production and distribution. As the UAE continues to expand its biosimilar portfolio and promote their adoption, the biosimilars market is set to witness further advancements, delivering enhanced healthcare outcomes and cost savings for patients and healthcare stakeholders.
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 United Arab Emirates (UAE) Biosimilars Market Overview |
3.1 United Arab Emirates (UAE) Country Macro Economic Indicators |
3.2 United Arab Emirates (UAE) Biosimilars Market Revenues & Volume, 2020 & 2027F |
3.3 United Arab Emirates (UAE) Biosimilars Market - Industry Life Cycle |
3.4 United Arab Emirates (UAE) Biosimilars Market - Porter's Five Forces |
3.5 United Arab Emirates (UAE) Biosimilars Market Revenues & Volume Share, By Product, 2020 & 2027F |
3.6 United Arab Emirates (UAE) Biosimilars Market Revenues & Volume Share, By Indication, 2020 & 2027F |
3.7 United Arab Emirates (UAE) Biosimilars Market Revenues & Volume Share, By Manufacturing, 2020 & 2027F |
4 United Arab Emirates (UAE) Biosimilars Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.3 Market Restraints |
5 United Arab Emirates (UAE) Biosimilars Market Trends |
6 United Arab Emirates (UAE) Biosimilars Market, By Types |
6.1 United Arab Emirates (UAE) Biosimilars Market, By Product |
6.1.1 Overview and Analysis |
6.1.2 United Arab Emirates (UAE) Biosimilars Market Revenues & Volume, By Product, 2018 - 2027F |
6.1.3 United Arab Emirates (UAE) Biosimilars Market Revenues & Volume, By Insulin, 2018 - 2027F |
6.1.4 United Arab Emirates (UAE) Biosimilars Market Revenues & Volume, By Follitropin, 2018 - 2027F |
6.1.5 United Arab Emirates (UAE) Biosimilars Market Revenues & Volume, By Calcitonin, 2018 - 2027F |
6.1.6 United Arab Emirates (UAE) Biosimilars Market Revenues & Volume, By Glucagon, 2018 - 2027F |
6.1.7 United Arab Emirates (UAE) Biosimilars Market Revenues & Volume, By Teriparatide, 2018 - 2027F |
6.1.8 United Arab Emirates (UAE) Biosimilars Market Revenues & Volume, By Others, 2018 - 2027F |
6.2 United Arab Emirates (UAE) Biosimilars Market, By Indication |
6.2.1 Overview and Analysis |
6.2.2 United Arab Emirates (UAE) Biosimilars Market Revenues & Volume, By Oncology, 2018 - 2027F |
6.2.3 United Arab Emirates (UAE) Biosimilars Market Revenues & Volume, By Offsite Treatment, 2018 - 2027F |
6.2.4 United Arab Emirates (UAE) Biosimilars Market Revenues & Volume, By Chronic Disorders, 2018 - 2027F |
6.2.5 United Arab Emirates (UAE) Biosimilars Market Revenues & Volume, By Blood Disorders, 2018 - 2027F |
6.2.6 United Arab Emirates (UAE) Biosimilars Market Revenues & Volume, By Infectious Diseases, 2018 - 2027F |
6.2.7 United Arab Emirates (UAE) Biosimilars Market Revenues & Volume, By Others, 2018 - 2027F |
6.3 United Arab Emirates (UAE) Biosimilars Market, By Manufacturing |
6.3.1 Overview and Analysis |
6.3.2 United Arab Emirates (UAE) Biosimilars Market Revenues & Volume, By Outsourced, 2018 - 2027F |
6.3.3 United Arab Emirates (UAE) Biosimilars Market Revenues & Volume, By In-house, 2018 - 2027F |
7 United Arab Emirates (UAE) Biosimilars Market Import-Export Trade Statistics |
7.1 United Arab Emirates (UAE) Biosimilars Market Export to Major Countries |
7.2 United Arab Emirates (UAE) Biosimilars Market Imports from Major Countries |
8 United Arab Emirates (UAE) Biosimilars Market Key Performance Indicators |
9 United Arab Emirates (UAE) Biosimilars Market - Opportunity Assessment |
9.1 United Arab Emirates (UAE) Biosimilars Market Opportunity Assessment, By Product, 2020 & 2027F |
9.2 United Arab Emirates (UAE) Biosimilars Market Opportunity Assessment, By Indication, 2020 & 2027F |
9.3 United Arab Emirates (UAE) Biosimilars Market Opportunity Assessment, By Manufacturing, 2020 & 2027F |
10 United Arab Emirates (UAE) Biosimilars Market - Competitive Landscape |
10.1 United Arab Emirates (UAE) Biosimilars Market Revenue Share, By Companies, 2020 |
10.2 United Arab Emirates (UAE) Biosimilars Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |